Van Hulzen Asset Management LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Van Hulzen Asset Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 2.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,288 shares of the company’s stock after selling 65 shares during the period. Van Hulzen Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,784,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Boston Family Office LLC raised its stake in shares of Eli Lilly and Company by 71.1% in the second quarter. Boston Family Office LLC now owns 9,037 shares of the company’s stock worth $7,045,000 after purchasing an additional 3,755 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Eli Lilly and Company by 80.4% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 287,936 shares of the company’s stock valued at $224,455,000 after acquiring an additional 128,369 shares during the period. Brentview Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 38.7% during the 2nd quarter. Brentview Investment Management LLC now owns 5,374 shares of the company’s stock valued at $4,189,000 after acquiring an additional 1,500 shares during the last quarter. Bare Financial Services Inc grew its stake in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the period. Finally, Prossimo Advisors LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $294,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LLY shares. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. BMO Capital Markets increased their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a report on Monday, November 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,058.86.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,057.73 on Tuesday. The stock has a market cap of $999.96 billion, a PE ratio of 69.13, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The firm has a fifty day moving average price of $895.42 and a 200-day moving average price of $802.48. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.